Avanir Pharmaceuticals Inc - Company & Market Research Reports

Following a company allows Research and Markets to customize your experience and provide personalized recommendations.

Avanir Pharmaceuticals focuses on the research, development and commercialization of novel medical and pharmaceutical treatments for people with central nervous system disorders. It primarily offers NUEDEXTA, a dual N-methyl-D-aspartate receptor antagonist and sigma-1 agonist for the treatment of pseudobulbar affect; and Docosanol 10% cream, an over-the-counter product for the treatment of cold sores. Avanir Pharmaceuticals was founded in 1988 and is headquartered in Aliso Viejo, California.

From
From
Alzheimer's Disease - Pipeline Review, H2 2018 - Product Thumbnail Image

Alzheimer's Disease - Pipeline Review, H2 2018

  • Drug Pipelines
  • 1333 Pages
From
Schizophrenia - Pipeline Review, H2 2018 - Product Thumbnail Image

Schizophrenia - Pipeline Review, H2 2018

  • Drug Pipelines
  • 321 Pages
From
From
Schizophrenia - Pipeline Review, H1 2018 - Product Thumbnail Image

Schizophrenia - Pipeline Review, H1 2018

  • Drug Pipelines
  • 334 Pages
From
From
From
From
Depression - Pipeline Review, H2 2018 - Product Thumbnail Image

Depression - Pipeline Review, H2 2018

  • Drug Pipelines
  • 504 Pages
From
Depression - Pipeline Review, H1 2018 - Product Thumbnail Image

Depression - Pipeline Review, H1 2018

  • Drug Pipelines
  • 490 Pages
From
From
From
From
From
From
From
Dyskinesia - Pipeline Insight, 2019 - Product Thumbnail Image

Dyskinesia - Pipeline Insight, 2019

  • Drug Pipelines
  • 70 Pages
From
Loading Indicator
adroll